RITONAVIR (r), 100mg, tab.
STD
DORARITO1T2
Valid Article
Account code:
60000
HS Code:
300490
Last Updated on:
20/12/2025, 22:07:35
Former
Code(s):
-X DORAZFR0546 DORAZFR0548
J05AE03
Anatomical Therapeutic Chemical Classification according to WHOCC
OC subscriptions: included in supply or field order tools (e.g. UniField)
|
|
SC subscriptions: included in supply or field tools
|
|
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
|
|
RITONAVIR (r)
Therapeutic Action
Antiretroviral, protease inhibitor (PI)
Indications
Booster for protease inhibitors (darunavir, lopinavir, atazanavir) in HIV infection. Not used as an antiretroviral on its own.
Combination of darunavir / ritonavir is the preferred boosted protease inhibitor option for ART if a protease inhibitor is needed.
Combinations of atazanavir + ritonavir or lopinavir + ritonavir can be used as alternatives if darunavir / ritonavir cannot be used.
Instructions for use
Ritonavir should not be used alone but in combination with other protease inhibitors.
Fixed-dose combinations (FDC) are available:
- DRV eq. 400mg base / r 50mg, tab.
- ATV 300mg / r 100mg, tab.
- LPV 40mg / r 10mg, granules, sachet
- LPV 100mg / r 25mg, tab.
- LPV 200mg / r 50mg, tab.
The 100 mg ritonavir tablet may be required to boost darunavir in patients with TB who are on protease inhibitor-based ART.
Storage
Below 25ºC